These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36459346)

  • 21. A regulatory perspective on issues and approaches in characterizing human metabolites.
    Davis-Bruno KL; Atrakchi A
    Chem Res Toxicol; 2006 Dec; 19(12):1561-3. PubMed ID: 17173368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The evolving landscape of drug products containing nanomaterials in the United States.
    D'Mello SR; Cruz CN; Chen ML; Kapoor M; Lee SL; Tyner KM
    Nat Nanotechnol; 2017 Jul; 12(6):523-529. PubMed ID: 28436961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA's Office of Pharmaceutical Quality.
    Fisher AC; Lee SL; Harris DP; Buhse L; Kozlowski S; Yu L; Kopcha M; Woodcock J
    Int J Pharm; 2016 Dec; 515(1-2):390-402. PubMed ID: 27773853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. US definitions, current use, and FDA stance on use of platelet-rich plasma in sports medicine.
    Beitzel K; Allen D; Apostolakos J; Russell RP; McCarthy MB; Gallo GJ; Cote MP; Mazzocca AD
    J Knee Surg; 2015 Feb; 28(1):29-34. PubMed ID: 25268794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.
    Poon R; Khanijow K; Umarjee S; Fadiran E; Yu M; Zhang L; Parekh A
    J Womens Health (Larchmt); 2013 Jul; 22(7):604-16. PubMed ID: 23768021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2020: A Record Year for Drug Approvals.
    Losben NL
    Sr Care Pharm; 2021 Apr; 36(4):174-175. PubMed ID: 33766189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulatory issues in clinical applications of cytokines and growth factors.
    Weiss KD; Siegel JP; Gerrard TL
    Prog Growth Factor Res; 1994; 5(2):213-22. PubMed ID: 7919225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian statistics in medical devices: innovation sparked by the FDA.
    Campbell G
    J Biopharm Stat; 2011 Sep; 21(5):871-87. PubMed ID: 21830920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. History, status, and politicization of the FDA.
    Wang W; Wertheimer AI
    Res Social Adm Pharm; 2022 May; 18(5):2811-2816. PubMed ID: 34215537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights into human factor studies conducted for US FDA-approved biological combination products.
    Patel R; Mehta M; Pipalava P; Dahiya M; Singh I; Jose V
    Expert Opin Drug Deliv; 2019 Dec; 16(12):1333-1353. PubMed ID: 31625768
    [No Abstract]   [Full Text] [Related]  

  • 31. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review.
    Tyner K; Sadrieh N
    Methods Mol Biol; 2011; 697():17-31. PubMed ID: 21116951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bovine sera used in the manufacture of biologicals: current concerns and policies of the U.S. Food and Drug Administration regarding the transmissible spongiform encephalopathies.
    Asher DM
    Dev Biol Stand; 1999; 99():41-4. PubMed ID: 10404874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory administrative databases in FDA's Center for Biologics Evaluation and Research: convergence toward a unified database.
    Smith JK
    AAPS J; 2013 Apr; 15(2):388-94. PubMed ID: 23269527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA's Benefit-Risk Framework for Human Drugs and Biologics: Role in Benefit-Risk Assessment and Analysis of Use for Drug Approvals.
    Lackey L; Thompson G; Eggers S
    Ther Innov Regul Sci; 2021 Jan; 55(1):170-179. PubMed ID: 32779045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Proposed Framework for Patient-Focused Policy at the U.S. Food and Drug Administration.
    Kuehn CM
    Biomedicines; 2019 Aug; 7(3):. PubMed ID: 31461892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDER risk assessment exercise to evaluate potential risks from the use of nanomaterials in drug products.
    Cruz CN; Tyner KM; Velazquez L; Hyams KC; Jacobs A; Shaw AB; Jiang W; Lionberger R; Hinderling P; Kong Y; Brown PC; Ghosh T; Strasinger C; Suarez-Sharp S; Henry D; Van Uitert M; Sadrieh N; Morefield E
    AAPS J; 2013 Jul; 15(3):623-8. PubMed ID: 23512727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Demystifying the U.S. Food and Drug Administration: I. Understanding agency structure and function.
    Levi B; Lisiecki J; Rubin P; D'Amico RA; Hume KM; Seward B; Cederna PS
    Plast Reconstr Surg; 2014 Jun; 133(6):1495-1501. PubMed ID: 24867731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomedical applications of tissue engineering technology: regulatory issues.
    Hellman KB
    Tissue Eng; 1995; 1(2):203-10. PubMed ID: 19877928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idle thoughts of a 'well-calibrated' Bayesian in clinical drug development.
    Grieve AP
    Pharm Stat; 2016; 15(2):96-108. PubMed ID: 26799060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design control considerations for biologic-device combination products.
    Anderson D; Liu R; Anand Subramony J; Cammack J
    Adv Drug Deliv Rev; 2017 Mar; 112():101-105. PubMed ID: 28088344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.